La Jolla Pharmaceutical Co. (Nasdaq: LJPC), a biotechnology company developing therapeutics targeting significant unmet diseases, announced Monday it has signed an option agreement with Stanford University that will add proprietary technology to the company’s programs.
The option agreement with Stanford allows La Jolla Pharmaceutical to test the technology, potentially adding product opportunities to La Jolla Pharmaceutical’s pipeline.
La Jolla Pharmaceutical is currently testing novel oral formulations using the technology in an animal model of non-alcoholic steatohepatitis (NASH). If successful, these product candidates will add to the company’s growing pipeline that includes treatments for chronic kidney disease, hepatorenal syndrome, chronic iron overload and rare diseases.
6455 Nancy Ridge Dr.
San Diego, CA 92121